Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588738 · ClinicalTrials.gov registry record · Phase 3
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
A Phase 3 study of Plaque Psoriasis, sponsored by Alumis.
- Active
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
- 20
- Study locations
NCT06588738 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Alumis. The registered enrollment target is 840 participants, above the 397-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (112% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06588738, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Alumis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ESK-001
- DRUG Apremilast
Study Locations (20)
California
- Zenith Research Inc. - Beverly Hills
- Raoof MD - Encino
- Long Beach Research Institute - Long Beach
- Dermatology Research Associates - Los Angeles
- Empire Clinical Research - Pomona - Pomona
- Integrative Skin Science and Research - Sacramento
- UC San Diego - San Diego
- Southern California Clinical Research - Santa Ana
- Clinical Science Institute Dermatology Institute - Santa Monica
Florida
- FXM Clinical Research Ft. Lauderdale LLC - Fort Lauderdale
- Direct Helpers Research Center (DHRC) - Hialeah
- AppleMed Research Group under WCG - Miami
- FAX Pharma Clinical Research Inc - Miami
- FXM Clinical Research - Miami LLC - Miami
- Las Mercedes Medical Research - Miami
- FXM Clinical Research Miramar LLC - Miramar
- Renstar Medical Research - Ocala
Arizona
- Chandler Clinical Trials - Chandler
- Noble Clinical Research - Tucson
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588738
The ClinicalTrials.gov registry entry for NCT06588738 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 397-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (112% higher). The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06588738 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06588738 about?
NCT06588738 is a clinical study titled "A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001". The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study include...
What is the current status of trial NCT06588738?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2024-08-20. Estimated completion is 2025-12.
What conditions does trial NCT06588738 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06588738?
The interventions under investigation include: Placebo (DRUG), ESK-001 (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT06588738?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588738 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.